Key clinical point: Adding tucatinib to trastuzumab and capecitabine improved survival in patients with HER2-positive breast cancer and brain metastasis.
Major finding: The median overall survival was 18.1 months in the tucatinib arm and 12 months in patients who received only trastuzumab and capecitabine (P = .005).
Study details: Analysis of data from the phase 2 HER2CLIMB trial, limited to the 291 women with brain metastases at baseline.
Disclosures: The research was funded by tucatinib’s maker, Seattle Genetics. Investigators disclosed financial relationships with Seattle Genetics, including employment.
Lin NU et al. ASCO 2020, Abstract 1005.